Syros Pharmaceuticals Inc (OQ:SYRS)

Business Focus: Biopharmaceuticals

Sector:  Healthcare Industry:  Pharmaceuticals
See Regulatory Filings on SEC
Company Contact
Tel: N/A
IR: See website
Key People
Peter Wirth
Independent Chairman of the Board
Nancy A. Simonian
President, Chief Executive Officer, Director
Joseph J. Ferra
Chief Financial Officer
Eric R. Olson
Chief Scientific Officer
Gerald E. Quirk
Chief Legal & Administrative Officer
David A. Roth
Chief Medical Officer
Jeremy P. Springhorn
Chief Business Officer
Business Overview
Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines. The Company's drug programs include SY-1425 (retinoic acid receptor alpha (RARa) agonist) and SY-1365 (cyclin-dependent kinase 7 (CDK7) inhibitor). SY-1425 (tamibarotene) is an oral, potent and selective agonist, or activator, of the transcription factor RARa. SY-1365 is a small molecule inhibitor of the transcriptional kinase known as CDK7. The Company is using its platform to analyze gene expression programs across additional cancers, solid tumors, inflammatory diseases and other diseases to find optimal points of therapeutic intervention in patients.
Financial Overview
For the six months ended 30 June 2020, Syros Pharmaceuticals Inc revenues increased from $916K to $5.6M. Net loss decreased 4% to $34.4M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Research & Development - Balancing value decrease of 1% to $18.5M (expense), General and Administrative - Balancing decrease of 2% to $7.3M (expense).
Employees: 83 as of Dec 31, 2019
Reporting Currency: U.S. Dollars
Enterprise value: $256.30M as of Jun 30, 2020
Annual revenue (TTM): $6.63M as of Jun 30, 2020
EBITDA (TTM): -$71.60M as of Jun 30, 2020
Net annual income (TTM): -$73.94M as of Jun 30, 2020
Free cash flow (TTM): -$47.52M as of Jun 30, 2020
Net Debt Last Fiscal Year: N/A
Shares outstanding: 45,762,169 as of Jul 31, 2020
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please subscribe. Our packages start at $1.00 plus tax for the first month.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.